Business Context and Reporting Period
This Form 8-K Current Report was filed by HALOZYME THERAPEUTICS, INC. on March 12, 2004. The filing reports a material change in the company's independent certifying accountants.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the change of auditors and does not contain financial statement data.
Material Changes
- Dismissal of Previous Accountant: On March 12, 2004, the Company dismissed Hall & Company as its independent accountants.
- Engagement of New Accountant: The Company engaged Cacciamatta Accountancy Corporation as its new independent accountants effective March 12, 2004.
- Audit History: Hall & Company's reports for the past two fiscal years contained no adverse opinions, disclaimers, or qualifications regarding uncertainty, audit scope, or accounting principles.
- Disagreements: The Company reported no disagreements with Hall & Company on accounting principles, practices, or auditing scope during the two most recent fiscal years or through the date of the report.
Guidance, Outlook, and Risks
The filing does not provide guidance, outlook, or management commentary regarding future financial performance. The primary risk disclosed is the change in independent auditors, though the filing explicitly states there were no reportable events or disagreements precipitating the change.
Investor Verification Checklist
- Verify the content of the letter from Hall & Company (Exhibit 16.1) to confirm their agreement with the Company's statements regarding the dismissal.
- Confirm the qualifications and independence of the new auditor, Cacciamatta Accountancy Corporation.
- Review subsequent filings to ensure the transition of accounting responsibilities did not impact the audit of the most recent fiscal year.